Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of SN2001 in Healthy Adult Subjects

NCT07059403 is registered in ClinicalTrials.gov with Chimivac INC as lead sponsor.

NCT NCT07059403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07059403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of SN2001 in Healthy Adult Subjects
Lead sponsor
Chimivac INC
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 19, 2025
Completion date
April 30, 2027
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b infection